 |
Indication & Dosage |
| |
| |
| Oral |
| PROPHYLAXIS OF ACUTE RENAL GRAFT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. Elderly: As mycophenolic acid: Max: 720 mg bid. |
| Max Dosage: 2 g/day. As mycophenolic acid: 720 mg bid. |
| |
| Oral |
| PROPHYLAXIS OF ACUTE RENAL GRAFT REJECTION |
| Child:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| Max Dosage: 1,440 mg |
| |
| Oral |
| PROPHYLAXIS OF CARDIAC GRAFT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| |
| Oral |
| PROPHYLAXIS OF HEPATIC TRANSPLANT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| |
| Intravenous |
| PROPHYLAXIS OF ACUTE RENAL GRAFT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| |
| Intravenous |
| PROPHYLAXIS OF HEPATIC TRANSPLANT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| |
| Intravenous |
| PROPHYLAXIS OF CARDIAC GRAFT REJECTION |
| Adult:
As mycophenolate mofetil: 1 g bid starting within 72 hr of transplantation. |
| Max Dosage: 2 g/day. As mycophenolic acid: 720 mg bid. |
|
| |
|
| Administration |
Should be taken on an empty stomach (i.e. At least one hour before food or four hours after food). (Take on an empty stomach. In stable renal transplant patients, may be administered w/ meals if necessary.) |
| |
|
| Precautions |
Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Diarrhoea, vomiting, GI haemorrhage and perforation; leucopenia; asthenia, pain, headache, anaemia, thrombocytopenia, renal tubular necrosis, haematuria, BP changes, hyperglycaemia, disturbances of electrolytes and blood lipids, peripheral oedema, dyspnoea, cough, acne, rash, alopecia, dizziness, insomnia, paraesthesia, tremor, hypersensitivity reactions, pancreatitis, hepatitis. |
| |
|
| Adverse Drug Reactions |
Angioedema, anaphylaxis, fatal pulmonary fibrosis. |
| |
|
| Interactions |
Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines. |
| |
|
|
|
